UP - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • He, Jing; Zhang, Xia; Wei, Yunbo; Sun, Xiaolin; Chen, Yaping; Deng, Jun; Jin, Yuebo; Gan, Yuzhou; Hu, Xin; Jia, Rulin; Xu, Chuanhui; Hou, Zhaohua; Leong, Yew Ann; Zhu, Lei; Feng, Jinhong; An, Yuan; Jia, Yuan; Li, Chun; Liu, Xu; Ye, Hua; Ren, Limin; Li, Ru; Yao, Haihong; Li, Yuhui; Chen, Shi; Zhang, Xuewu; Su, Yin; Guo, Jianping; Shen, Nan; Morand, Eric F; Yu, Di; Li, Zhanguo

    Nature medicine, 09/2016, Letnik: 22, Številka: 9
    Journal Article

    Systemic lupus erythematosus (SLE) is a potentially life-threatening autoimmune disease characterized by altered balance of activity between effector and regulatory CD4(+) T cells. The homeostasis of CD4(+) T cell subsets is regulated by interleukin (IL)-2, and reduced production of IL-2 by T cells is observed in individuals with SLE. Here we report that treatment with low-dose recombinant human IL-2 selectively modulated the abundance of regulatory T (Treg) cells, follicular helper T (TFH) cells and IL-17-producing helper T (TH17) cells, but not TH1 or TH2 cells, accompanied by marked reductions of disease activity in patients with SLE.